Novartis Predicts $4 Billion Peak Sales For Gleevec/Tasigna Franchise
This article was originally published in The Pink Sheet Daily
Executive Summary
Only weeks into Tasigna's launch, Novartis is optimistic doctors will opt for nilotinib’s side-effect profile over Bristol’s Sprycel for Gleevec-resistant CML, Oncology CEO Epstein says.
You may also be interested in...
High-Dose Gleevec Works Faster, Not Longer
Phase III trial in CML misses primary endpoint.
High-Dose Gleevec Works Faster, Not Longer
Phase III trial in CML misses primary endpoint.
Bristol Counters Tasigna Approval With “Improved” Sprycel Labeling In CML
Chronic-phase CML patients are recommended to take dasatinib 100 mg once daily, a dose associated with the same efficacy and less fluid retention than twice daily 70 mg dosing.